COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D HC QHC Q Vitamin CV.C ZincZn PVP-IPVP-I REGNREGN LY-CoVLY RemdesivirRMD
HCQ study #138 of 231
9/22 Late treatment study
Serrano et al., Ann. Oncol., 2020, Sep, 31, S1026, doi:10.1016/j.annonc.2020.08.1830 (Peer Reviewed)
COVID-19 and lung cancer: What do we know?
Source   PDF   Share   Tweet
Small retrospective study of 22 lung cancer patients, 14 treated with HCQ+AZ, showing HCQ+AZ mortality relative risk RR 0.57, p = 0.145.

Serrano et al., 9/22/2020, retrospective, Spain, Europe, peer-reviewed, 8 authors.
risk of death, 43.0% lower, RR 0.57, p = 0.14, treatment 6 of 14 (42.9%), control 6 of 8 (75.0%).
Details of all 231 studies    Meta analysis
Please send us corrections, updates, or comments.
Submit